INTRODUCTION
Arsenic is a metalloid that naturally exists in our environment. It has been considered as a potent carcinogen, and chronic exposure to arsenic may lead to various types of tumours, including lung, renal, prostate, bladder and skin cancers and other malignancies. In addition, long-term exposure to arsenic is associated with some chronic diseases, such as blackfoot, diabetes and cardiovascular diseases [1] .
However, one of the major inorganic forms, ATO (arsenic trioxide), is a chemotherapeutic agent approved by the U.S. Food and Drug Administration in 2000 for the treatment of APL (acute promyelocytic leukaemia) patients. ATO (<2 μM) has an antitumoral effect by inducing cell death or differentiation of APL cells [2] . Clinical trials with arsenic-based drugs for the treatment of various forms of cancer are in progress [3] . Several modes of action for the antitumoral effects of ATO have been proposed, such as ROS (reactive oxygen species) production, up-regulation of pro-apoptotic proteins and induction of some death-associated signalling [1, 4] . Therefore we suggest that ATO is a multi-target drug that may be more effective than single-target agents in cancer therapy.
HCC (hepatocellular carcinoma) is the fifth most common cancer worldwide with a poor prognosis, mainly due to a high recurrence rate and ineffective therapy [5] . Moreover, the common chemotherapy drug used in HCC may induce side effects and chemotherapy resistance [6] . Therefore development of new drugs or therapies for the treatment of HCC is urgently needed.
A Phase II trial has been conducted to evaluate the efficacy and toxicity of single-agent ATO in patients with HCC [7] . However, the trial shows that use of arsenic as a single agent is not effective against HCC and should be combined with other chemotherapeutic agents. Results accumulated so far indicate that ATO can induce some protective signal pathways, which negatively regulate its antitumoral effects. In combination with a pharmacological inhibitor of protective signalling, such as PI3K (phosphoinositide 3-kinase)/Akt and JNK (c-Jun N-terminal kinase) inhibitors, ATO can enhance ATO-induced growthinhibitory and pro-apoptotic responses [4, 8, 9] . Therefore the diverse biological function of ATO should be investigated further to develop new therapeutic strategies for its promising clinical uses.
Previously, we have found that two opposing signal pathways were involved in the ATO-induced apoptosis of A431 cells. The EGFR [EGF (epidermal growth factor) receptor]/ERK (extracellular-signal-regulated kinase) pathway can be activated by ATO to induce p21 WAF1/CIP1 (p21) expression and the resultant apoptosis. In contrast, the JNK pathway acts as a negative regulator in ATO-induced p21 expression [10, 11] . Furthermore, we elucidated that JNK-induced c-Jun phosphorylation can recruit the TGIF [TG-interacting factor; also known as TGF-β (transforming growth factor-β)-induced factor homeobox 1; HUGO gene symbol TGIF1]-HDAC1 (histone deacetylase 1) complex to Sp1 (specificity protein 1) sites at the p21 promoter to suppress its activation. We hypothesize that blockage of the JNK pathway or knockdown of TGIF can enhance ATO-induced cancer cell apoptosis [9, 12] .
TGIF is one of the TALE (three-amino-acid loop extension) subfamily of atypical homeodomain proteins. It functions as a transcriptional repressor/co-repressor competing with coactivators for Smad interactions, and recruits HDAC1 to repress TGF-β/Smad-mediated signalling [13] . In humans, the TGIF gene was mapped to the region at 18p11.3. Mutations in the TGIF gene have been found in patients with HPE (holoprosencephaly), a severe brain and craniofacial malformation associated with mental retardation [14] .
TGF-β is a pluripotent cytokine that regulates a broad range of biological processes, including proliferation, migration, apoptosis and differentiation. Its signalling pathway shows a dual functional role in tumour suppression and oncogenic effects in various cancers [15, 16] . Through its serine/threonine kinase receptor complexes, TGF-β phosphorylates cytoplasmic mediators, the Smads, which may translocate to the nucleus and co-operate with transcriptional co-activators or co-repressors to regulate various TGF-β-responsive genes [16] . In response to TGF-β in HepG2 cells, Smad3/4 associates with c-Jun to transcriptionally activate p21 at Sp1-binding sites, leading to p21-dependent cellular senescence [17] , and thus eliciting its antitumoral effects [18] .
As described above, TGIF can restrict TGF-β signalling through multiple binding partners in the nucleus; this implies that TGIF may be involved in some phenomena of cancer. Overexpression of TGIF was also found in EGF-regulated hepatocellular carcinogenesis in mice [19] . Therefore the role of TGIF in HCC should be further elucidated. So far, evidence of the regulation of TGIF is limited. EGF, as well as HGF (hepatocyte growth factor), activates the ERK pathway to phosphorylate C-terminal residues of TGIF to increase its protein stability [20, 21] . Insulin up-regulates TGIF by stabilizing its protein against degradation via ERK and PI3K activation in 3T3-L1 preadipocytes [22] .
The results of the present study show that ATO can activate TGF-β signalling to induce p21 expression, and finally results in apoptosis in HepG2 cells. However, TGIF expression was also increased due to the fact that HuR (human antigen R) bound to TGIF mRNA to enhance its mRNA stability by ATO treatment. The EGFR/PI3K/Akt pathway was shown to regulate this posttranscriptional regulation mechanism. Furthermore, knockdown of TGIF could enhance the cytotoxic effects of ATO on HCC cells.
EXPERIMENTAL

Reagents and antibodies
ATO, actinomycin D, wortmannin, LY294002, Protein A-agarose beads and streptavidin-agarose were purchased from SigmaAldrich. The Wizard Plus MiniPrep DNA purification system, Pfu polymerase, luciferase plasmid pGL-3 and the luciferase assay system were obtained from Promega. Cycloheximide and PD153035 were purchased from Calbiochem. U0126 and the antiphospho-Smad3 antibody were purchased from Cell Signaling Technology. 
Cell culture
The liver cancer cell lines HepG2 and Huh7 were both maintained in DMEM supplemented with 10 % (v/v) fetal bovine serum, 100 μg/ml streptomycin and 100 units/ml penicillin. Cells were grown at 37
• C in a humidified atmosphere of air/CO 2 (19:1, v/v).
Western blot analysis
Cell lysates (30 μg) were separated by SDS/PAGE (12 % gels), and then transferred on to a PVDF membrane using a semi-dry blotting apparatus. After blocking with non-fat dried skimmed milk, antibodies against TGIF, phospho-ERK, ERK, phospho-Akt, Akt, TGF-βRII, phospho-Smad3, HuR, nucleolin, Smad3, cleaved caspase 3 and β-actin were used as primary antibodies. Rabbit or mouse IgG-specific antibodies conjugated to horseradish peroxidase were used as secondary antibodies. After development with an ECL (enhanced chemiluminescence) kit (GE Healthcare), the density of the immunoblots was determined using an image analysis system installed with BIO-ID software (Vilber Lourmat, France).
RT (reverse transcription)-PCR
A sense primer (5 -AGATCTGAATTGTGCCAGTGTTTCTCT-TTG-3 ) and an antisense primer (5 -CCATGGCGGCGCTG-TCAGAGTGAG-3 ) corresponding to the nucleotide sequence of human TGIF were used. The RT-PCR method was performed according to the manufacturer's instructions with a slight modification. The mixture contained 3 μg of total RNA, 2.5 μM oligo(dT), 1.5 mM MgCl 2 , 0.01 M DTT (dithiothreitol) and 200 units of SuperScript TM III reverse transcriptase in a total volume of 20 μl. The products were amplified on an Eppendorf MasterCycler under the following conditions. The RT steps consisted of an RT step (55
• C for 50 min) and a denaturation step (95
• C for 5 min). The PCR steps consisted of a denaturation step (95
• C for 30 s), a primer annealing step (58 • C for 30 s) and an elongation step (72
• C for 1 min) for 30 cycles. For the final step, the duration of the elongation step was 7 min. Finally, samples were mixed with loading buffer (50 mM Tris/HCl, 10 mM EDTA and 0.25 % Bromophenol Blue) and loaded on to a 1 % agarose gel containing 0.1 μg/ml ethidium bromide. The agarose gels were run at 135 V for 20 min in a TAE (Tris/acetate/EDTA) buffer. The gels were observed and photographed under UV light.
Real-time PCR
Total RNA was isolated from cells using TRIzol ® RNA solution. DNase I-treated RNA (2 μg) was reverse-transcribed using SuperScript TM III and oligo(dT) primers. Real-time PCR was conducted using the SYBR Green PCR Master Mix (Qiagen) and was processed on a LightCycler PCR and detection system (Roche Diagnostics). Each reaction (25 μl) was run in duplicate and contained 1 μl of cDNA template along with 0.4 μM TGIF primers (sense, 5 -CGCTACAGGTCTGTAACTGGTTC-3 ; antisense, 5 -GATGCCCATCACGGACTC-3 ) or β-actin primers (sense, 5 -TCCCTGGAGAAGAGCTACGA-3 ; antisense, 5 -ACTCCATGCCCAGGAAGG-3 ). Cycling parameters were 95
• C for 15 min to activate DNA polymerase, followed by 40 cycles of 95
• C for 15 s, 60
• C for 20 s, and 72
• C for 30 s. Melting curves were generated at the end of the reaction. Threshold cycles (C t ) for each gene tested were normalized to the housekeeping β-actin gene value ( C t ) and every experimental sample was referred to its control ( C t ). Fold change values were expressed as 2 − Ct .
DNA constructs, transient transfection and reporter gene assay
The full-length cDNAs of the human SMAD2/3/4 genes were amplified by PCR. The PCR products were digested with EcoRI/XhoI to generate fragments which were then ligated into the pcDNA3.1( + ) expression vector containing the CMV (cytomegalovirus) promoter and validated by sequencing.
The human TGIF promoter from − 2393 to + 119 bp was cloned by PCR using two specific primers (sense, 5 -AGATCTGAATTGTGCCAGTGTTTCTCTTTG-3 ; antisense, 5 -CCATGGCGGCGCTGTCAGAGTGAG-3 ) with human genomic DNA from A431 cells as a template. The products of PCR were cloned into the T&A cloning vector (Yeastern Biotech), and then confirmed by DNA sequencing. After BglII and NcoI digestion, the fragments were then subcloned into the pGL3-basic vector (Promega). The 3 -UTR (3 -untranslated region) of TGIF (448 bp) was amplified from human HepG2 cells by RT-RCR, and then cloned into the pGL3 vector (Promega) and designated pGLTG3UTR.
The transfection method was performed using Lipofectamine • C in a humidified atmosphere of air/CO 2 (19:1) for a further 48 h, and then lysed for the measurement of luciferase activity as described previously [23] . The luciferase activity was determined and normalized to the amount of total protein.
Flow cytometry analysis
Cell death was evaluated by flow cytometry after staining with FITC-conjugated Annexin V and 0.5 μg/ml PI (propidium iodide). An Annexin V-FITC apoptosis detection kit (Biovision) was used to detect early apoptosis according to the manufacturer's instructions with slight modifications. After transfection for 24 h as described above, HepG2 cells were harvested and washed twice with ice-cold PBS and resuspended in 100 μl of binding buffer (Biovision). Annexin V (5 μl) and PI (10 μl) were added and the mixture was incubated for 15 min in the dark. Finally, 400 μl of binding buffer was added to the cells, and the mixture was analysed with a flow cytometer (FACSCalibur; BD Biosciences).
In vitro RNA synthesis and biotin-labelled RNA probe pull-down assay
The pGLTG3UTR plasmids were linearized to serve as templates to generate RNA probes for the pull-down assay. The RNAs were synthesized using the Riboprobe In Vitro Transcription System (Promega). Briefly, 1 μg of linearized DNA template was transcribed by T7 polymerase in the presence of 2.5 mM UTP, ATP and GTP, 1 mM CTP and 10 mM biotin-CTP for 1.5 h at 37
• C in each 30 μl reaction mixture. The reaction was stopped by adding 2 units of RQ1 RNase-free DNase I (Promega) for 15 min at 37
• C. The RNA was purified using MicroSpin G-25 columns. For the RNA probe pull-down assay, the biotinylated TGIF 3 -UTR was incubated with HepG2 cytosolic lysates at room temperature for 1 h. The complexes were isolated using streptavidin-conjugated agarose beads, the binding proteins in the pull-down complex were analysed by Western blotting using specific antibodies recognizing HuR and nucleolin, and then visualized by ECL (GE Healthcare).
RNA immunoprecipitation
HepG2 cells were treated with lysis buffer [10 mM Hepes (pH 8.0), 10 mM KCl, 1.5 mM MgCl 2 and 500 units of RNaseOUT] for 10 min on ice. The cellular extract was incubated with anti-HuR antibody or mouse control IgG and Protein A/G-agarose beads at 4
• C overnight followed by centrifugation (3300 g for 2 min at 4
• C). The immunoprecipitated protein-RNA complexes were washed three times with lysis buffer, and RNAs were extracted using TRIzol ® reagent. The TGIF 3 -UTR was detected by RT-PCR (primers used were sense, 5 -CCCGGGCCCATTTTCAAGCAAAAC-3 ; antisense, 5 -AGATCTATGTCATGAAAAAAAAGGCATCA-3 ).
Statistical analysis
A representative result is presented, and all experiments have been performed at least three times. The statistical analysis was determined using Student's t test. All values are displayed as means + − S.D. for three determinations (*P < 0.05, **P < 0.01 and ***P < 0.001 compared with the vehicle).
RESULTS
ATO increased p21 expression and cell apoptosis by activating the TGF-β signalling pathway
As described previously, TGF-β signalling plays an inhibitory role in the growth of HCC [18, 24] . In hepatoma HepG2 cells, 5 μM ATO could increase Smad3 phosphorylation, and Smad3 protein and p21 expression in a time-dependent manner ( Figure 1A) . Transient overexpression of Smad3 in HepG2 cells followed by ATO treatment for 4 h could further enhance p21 promoter activity ( Figure 1B) . Conversely, knockdown of Smad3 expression by shRNA could suppress ATO-induced p21 promoter activation and protein expression ( Figure 1C ). In addition, treatment with 5 μM ATO for 20 h increased the active form of caspase 3 expression and cleaved PARP in HepG2 cells, indicating that cellular apoptosis had occurred. However, knockdown of Smad3, followed by treatment with ATO, could suppress the apoptotic events ( Figure 1D ). Thus we suggest that TGF-β signalling is involved in ATO-induced p21 expression and apoptosis in HepG2 cells.
ATO induced TGIF expression and led to the attenuation of p21 activation
ATO was shown to induce cell apoptosis; however, the effect for treating HCC in Phase II trials is not very promising. It will be interesting to identify the factor which antagonizes the ATOinduced apoptotic effect. Previously, we have demonstrated that transient overexpression of TGIF could inhibit ATO-induced p21 expression in A431 cells [9, 11, 12] . In HepG2 cells, transient overexpression of TGIF could also inhibit ATO-induced p21 promoter activation (Figure 2A , top panel) and protein expression (Figure 2A , bottom panel) in a dose-dependent manner. This result prompted us to examine whether ATO can induce TGIF expression in HCC. As shown in Figures 2(B) and 2(C), TGIF mRNA and protein expression was induced by ATO stimulation in a time-dependent manner in HepG2 and Huh7 cells respectively. The multiple bands of TGIF shown in the Western blot analysis might be isoforms of the protein, as described previously [25] . This result implies that TGIF may be the factor that interferes with ATO-induced apoptosis.
ATO-induced TGIF expression was dependent on a post-transcriptional regulation mechanism
To determine whether ATO controls the transcriptional activity of TGIF, a reporter containing 2.5 kb of the human TGIF promoter ( −2393 to + 119 bp) fused with the firefly luciferase gene was constructed, as described in the Experimental section. Then, we transiently transfected the reporter into hepatoma cells and measured its promoter activity in response to ATO. As shown in Figure 3(A) , ATO could only slightly induce TGIF promoter activity in HepG2 cells. Compared with the fold increase of TGIF mRNA after ATO treatment ( Figure 2B , approximately 3.8-fold), this result highlighted that an mRNA stability regulation mechanism may be involved in the expression of TGIF. Using actinomycin D to block the transcriptional event, we measured the degradation rate of TGIF in response to ATO by real-time PCR. As shown in Figure 3(B) , the degradation rate of TGIF mRNA slowed down after ATO treatment. A similar result was also obtained using a traditional RT-PCR assay ( Figure 3C ). To (A) HepG2 cells were transfected with TGIF-luc plasmids (0.5 μg) for 24 h, followed by treatment with 5 μM ATO for various time periods, and then harvested for measurement of luciferase activity. HepG2 cells were treated with or without 5 μM ATO for 1 h followed by addition of 5 μg/ml actinomycin D (ActD) for another 1 h or 2 h respectively. TGIF mRNA expression was examined by real-time PCR (B) or RT-PCR (C) as described in the Experimental section. **P < 0.01 compared with control cells (n = 6). (D) HepG2 cells were transfected with pGL-luc (top panel) or pGLTG3UTR (bottom panel) respectively, followed by treatment with 5 μM ATO for 2 h, and then harvested for measurement of luciferase activity. *P < 0.05 compared with control cells (n = 6). gapdh, glyceraldehyde-3-phosphate dehydrogenase.
demonstrate further whether the 3 -UTR of TGIF mRNA plays an important role in regulating the mRNA stability, a reporter containing the 3 -UTR of TGIF mRNA was constructed. We found that treatment with ATO for 2 h led to an increase in TGIF 3 -UTR reporter activity by up to 1.5-fold ( Figure 3D, bottom panel) . This indicates that ATO-induced TGIF expression is based on regulating mRNA stability.
ATO increased the interaction between HuR and the TGIF mRNA 3 -UTR
An increased interaction between RNA-binding proteins, such as HuR, nucleolin and hnRNPK (heterogeneous nuclear ribonucleoprotein K), with the 3 -UTR plays an important role in the regulation of mRNA stability under stimuli [26, 27] . Therefore the involvement of these RNAbinding proteins in the regulation of TGIF mRNA in response to ATO was investigated. A pull-down assay, as described in the Experimental section, showed increased binding of HuR, but not nucleolin protein, to the biotin-labelled TGIF 3 -UTR with ATO treatment ( Figure 4A) ; however, protein expression of HuR and nucleolin was not changed after ATO treatment. These results indicate that ATO can enhance the binding of HuR to the TGIF 3 -UTR in vitro. Furthermore, the interaction of HuR with the TGIF 3 -UTR in vivo was explored using an RNA immunoprecipitation assay. We also found that more TGIF mRNA could be pulled down by ATO treatment than by vehicle ( Figure 4B ). In addition, reduction of the HuR protein expression by siRNA technology abolished the ATOinduced TGIF expression ( Figure 4C ). HuR siRNA reduced the level of HuR protein to approximately 50 %, as well as the level of ATO-induced TGIF expression being decreased to approximately 50 % after transfection for 24 h.
Collectively, these results indicate that HuR physically interacts with the TGIF mRNA 3 -UTR to stabilize and increase its mRNA expression in response to ATO.
The EGFR/PI3K signalling pathway mediated ATO-induced TGIF expression
EGF, as well as HGF, signalling activates the ERK pathway leading to phosphorylation of TGIF to enhance its protein stability [20, 21] . We also found that ATO could regulate p21 expression via EGFR-associated signalling in A431 cells [10, 11] . To explore whether the EGFR-associated signalling pathway was involved in the ATO-induced TGIF expression in hepatoma cells, the EGFR inhibitor PD153035 was used to address this question. As shown in Figure 5 , PD153035 completely blocked ATO-induced TGIF mRNA and protein expression ( Figure 5A ). In addition, U0126, a specific MEK [MAPK (mitogen-activated protein kinase)/ERK kinase] inhibitor, could block ATO-induced sustained ERK1/2 phosphorylation, but it could not change the expression of TGIF protein ( Figure 5B ). This indicates that ERK1/2 activation is not involved in ATO-induced TGIF expression.
The PI3K/Akt signalling pathway is well-known for its effects in promoting cell survival [28] . Accumulated results suggest that specific pharmacological inhibitors to the PI3K/Akt survival signal can improve ATO-induced leukaemia cell apoptosis [8, 29] . It has also been shown that insulin increases the TGIF protein level through the PI3K/Akt signalling pathway in the differentiation of preadipocytes [22] . In HepG2 cells, we found that ATO was able to induce Akt (Ser 473 ) phosphorylation in a time-dependent manner ( Figure 5C ), and pre-treatment with the EGFR inhibitor PD153035 could block the phosphorylation (results not shown). Furthermore, pre-treatment with the PI3K inhibitor LY294002 (results not shown) or wortmannin followed by ATO stimulation could inhibit TGIF expression ( Figure 5D ). Therefore we suggest that the EGFR/PI3K-associated signalling pathway is involved in ATO-induced TGIF expression.
The EGFR/PI3K/Akt signalling pathway regulated TGIF mRNA stability
We further explored the signalling pathways involved in regulating TGIF mRNA stability in response to ATO. Pre-treatment with the EGFR inhibitor PD153035 was able to inhibit ATO-induced TGIF 3 -UTR reporter activity ( Figure 6A ). In addition, pretreatment with the PI3K inhibitors wortmannin or LY294002 (results not shown) was able to inhibit ATO-induced TGIF 3 -UTR reporter activity ( Figure 6B ). Moreover, silencing of Akt1 by its shRNA also blocked ATO-induced TGIF 3 -UTR reporter activity ( Figure 6C ), as well as TGIF protein expression ( Figure 6D ). Therefore we suggest that the EGFR/PI3K/Akt pathway is involved in ATO-induced post-transcriptional regulation of TGIF.
Knockdown of TGIF enhanced ATO-induced apoptosis
According to the results described above, we suggest that TGIF may play an antagonistic role in the ATO-induced apoptosis of HepG2 cells. Therefore knockdown of TGIF followed by treatment with 5 μM ATO for 20 h in HepG2 cells was performed and then Annexin V/PI staining followed by flow cytometry was used to measure the apoptotic cells. As shown in Figure 7 (B), ATO-treated cells were 11.4 % Annexin V + /PI − (early apoptotic) and 3.9 % Annexin V + /PI + (later apoptotic), whereas the vehicle cells were 1.8 % Annexin V + /PI − and 1.7 % Annexin V + /PI + ( Figure 7A ). In addition, when cells were transfected with TGIF shRNA (2 μg) followed by treatment with 5 μM ATO for 20 h, early apoptotic cells (Annexin V + /PI − ) were increased further to 21.4 % (Figure 7C) , and cleaved PARP expression was also increased, as analysed by Western blotting ( Figure 7E ). The knockdown efficiency of TGIF shRNA was measured to be approximately 80 % ( Figure 7E ). Therefore we suggest that silencing of TGIF can enhance ATO-induced apoptosis in HepG2 cells.
Collectively, we suggest that ATO can induce TGF-β signalling to increase p21 expression and results in HepG2 cell apoptosis. However, ATO can activate EGFR/PI3K/Akt signalling to induce TGIF expression via increasing the interaction between HuR and TGIF mRNA. The increase of TGIF expression can prevent the apoptosis induced by ATO (Figure 8 ).
DISCUSSION
Three interesting findings have emerged from the present study. First, we found that TGF-β signalling was involved in ATO-induced p21 expression and resultant apoptosis in HepG2 cells. TGF-β has dual roles in tumour suppression and tumour promotion. In the early stages of cancer, TGF-β/Smad is considered as a growth inhibitory pathway in many tumours, including HCC. However, in advanced cancer, TGF-β/Smad can enhance the progression and metastasis of tumours [24] . In HepG2 cells, TGF-β can induce p21 expression, and resultant cellular arrest, senescence or apoptosis, to have its antitumoral effects [17, 18, 24] . On the other hand, ATO can induce hepatocellular growth arrest or apoptosis through regulation of redox homoeostasis [30, 31] and PI3K/Akt signalling [32] , but not MAPK signalling [30] . It also has a potential role in cancer therapy to inhibit angiogenesis and VEGF (vascular endothelial growth factor) expression [33, 34] . Arsenic has a high affinity for thiol-containing enzymes and proteins, such as phosphatases, and is necessary for their normal cellular activity [35] . Therefore we suggest that ATO may inhibit phosphatases, specifically dephosphorylating TGF-βRs, to activate TGF-β signalling. However, the mechanisms involved should be elucidated further.
Secondly, TGIF was able to be up-regulated by ATO through a post-transcriptional regulation mechanism, and played an antagonistic role in ATO-induced hepatocellular apoptosis. TGIF has been implicated in various types of cancer. The imbalance of the TGIF-located chromosome (18p11) has been found in transitional cell carcinoma of the bladder [36] , and frequently overexpression of the region was found in oesophageal carcinoma by comparative genomic hybridization analysis [37] . In addition, overexpression of TGIF in EGF-induced HCC in mice was found [19] . Furthermore, TGIF can physically bind to phosphorylated c-Jun to recruit HDAC1 to suppress TGF-β/Smad-activated transcriptional activity [13, 38] or to suppress ATO-induced p21 expression in A431 cells [9, 12] and in hepatoma cells (Figure 2) . Interestingly, loss of WAF/KIP protein families (p21, p27 and p57) was reported to correlate with a poorer prognosis in HCC patients [39, 40] . In addition, TGIF also plays a role as a component of the ubiquitin ligase complex associated with degradation of Smad2 to promote cellular growth [41] . Sequestration of cPML (cytoplasmic promyelocytic leukaemia) proteins by TGIF in the nucleus can negatively regulate TGF-β signalling to promote cellular transformation [42] . Therefore how to regulate the WAF/KIP protein families and TGF-β signalling by TGIF should be addressed further in HCC.
Thirdly, ATO can increase TGIF mRNA stability through EGFR/PI3K/Akt signalling to regulate HuR binding to the TGIF mRNA 3 -UTR. EGF phosphorylates C-terminal residues of TGIF (Thr 235 and Thr 239 ) to increase its half-life through the EGFR/Ras/MEK/ERK pathway [20] . However, we found that pre-treatment with the MEK inhibitor U0126 could not block the ATO-induced TGIF protein up-regulation. Furthermore, overexpression of MEK1 did not increase TGIF expression (results not shown). In addition, the results of treatment with the protein synthesis inhibitor cycloheximide also indicated that the post-translational modification of TGIF was not regulated by ATO in hepatocytes. Using actinomycin D and 3 -UTR analysis, we found a novel mechanism whereby the ATO-induced EGFR/PI3K/Akt pathway regulated the stability of TGIF mRNA in HepG2 cells. Some RNA-binding proteins, such as HuR and nucleolin, have been reported to be involved in arsenicinduced stabilization of GADD45 (growth arrest and DNA damage 45) mRNA [43] . We also identified that the transacting factor HuR could bind to the TGIF mRNA 3 -UTR to increase its mRNA stability in response to ATO (Figure 4) . HuR, originally identified in Drosophila melanogaster to be essential for neural development [44] , belongs to a member of the embryonic lethal abnormal vision family of RNA-binding proteins [45] . It can selectively bind to AU-rich elementcontaining regions or uridine-rich stretches to stabilize mRNA expression of numerous anti-apoptosis-related genes, such as prothymosin α [46] , Bcl-2 and Mcl-1 [47] . In HCC cell lines, DNA methyltransferase 3B could also be regulated by the PI3K/Akt pathway to modulate HuR protein at the post-transcriptional level [48] .
In addition, the PI3K/Akt pathway is a well-known signal that promotes the proliferation and survival of cancer cells [49] . Thus selective pharmacological inhibitors of the PI3K/Akt pathway have been used to enhance ATO-induced apoptosis, not only in leukaemia cells [8, 50, 51] , but also in solid tumour cells [32, 52] . FOXO3A (Forkhead box 3A) [32] , mTOR (mammalian target of rapamycin)/p70 S6K (S6 kinase) [50] or p53 [51] might be regulated by the PI3K/Akt pathway to modulate ATO-induced apoptosis. We conclude that blockage of the PI3K/Akt pathway or knockdown of TGIF may be a novel strategy to overcome drug resistance and enhance the efficacy of ATO treatment in HCC.
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